-
Saudi PIF Retains Top Sovereign Wealth Fund Brand Title for Third Year
-
Banff Avenue Transforms into High-End Retail Hub Amid Local Business Concerns
-
Selena Gomez Launches Black Equality Fund to Support Racial Justice Organizations
-
Golden Minerals Completes Drilling Desierto, Argentina
-
The 2026 MDaudit Annual Benchmark Report Spotlights AI's Impact on Financial Risk as Payer Denials and Audits Continue an Upward Trajectory
-
MicroVision and Blue-Band to Support $3 Million Federally Funded Intelligent Transportation Initiative in Louisville, Kentucky
-
More Than Half of Teen AI Chatbot Users Use Them Daily, and 46% Say It Feels Like Talking to a Human, New Family Online Safety Institute Research Finds
-
QNX Brings Physical AI and Next-Generation Software-Defined Vehicle Innovation to CES 2027
-
Arrive AI Eliminates All Debt Through Preferred Equity Exchange
-
multiQure Begins Manufacturing Phase of MQ-201 Gene Therapy for First Huntington's Disease Patients - U.S.-Based Andelyn Biosciences Selected as Manufacturing Partner
-
Valion Bio Welcomes Former U.S. Army Regulatory Leader and Biotech CEO Dr. Armand Balboni as Advisor in Run-up to Entolimod Therapeutic Efficacy Data Readout
-
Skilled Nursing Facilities Face 2027 Revenue Cycle Reckoning as Payer Burdens Reshape Admissions and Outsourcing
-
Karbon-X (OTCQB:KARX) Enters California's Multi-Billion-Dollar Compliance Carbon Market Following CITSS Approval
-
Greene Concepts Connects Consumer Needs with Manufacturing Strategy
-
Helio Corporation Engages CORE IR to Provide Investor Relations, Capital Markets Advisory and Media Relations Services
-
Guanajuato Silver Reports Q3 Operating and Financial Results
-
Gamma Resources Announces Expansion of Mesa Arc Uranium Project in New Mexico to 4,760 Acres, Completes Radon Flux Baseline Survey
-
Trustpoint Xposure Completes More Than 200 AI Visibility Audits Across Professional Services
-
NoHo, Inc. Acquires Four Placer Gold Claims in Clark County, Nevada from Gold Stake Mining Inc.
-
IRS Shuts Down FIRE Today: What Information Return Filers Need to Know Before the 2027 Filing Season
-
First Canadian Graphite Reports 43.9% Graphitic Carbon Sample and Encouraging Coarse-Flake Characteristics at Zone 13 at Lac Guéret South
-
LASE to Premiere Quantum Bullet(TM) at Counter UAS Technology Conference in Washington, D.C.
-
American Critical Minerals Reports High Grade Potash Intersection of 6.55m Grading 38.51 wt.% KCl at its Green River Project, Utah
-
Hemogenyx Pharmaceuticals PLC - Chairman Receives Prestigious Award
-
InterContinental Hotels Group PLC Announces Transaction in Own Shares - November 19
-
Bob's Watches Founder Paul Altieri Unveils Private Collection of Vintage Rolex Watches in New Book, "NOT FOR SALE"
-
Making the Most of a Long Weekend Without Leaving Town
-
Lumber's Union CBA Agent Launches in Sage Agent Marketplace to Help Simplify Union Payroll Compliance
-
Paul Scribner on General Holdings Limited's Role as a Principal Investor in Complex, Cross-Border Opportunities
-
Best Gold IRA Rollover Companies 2026 Announced: How to Choose and Gold IRA Rollover Basics Explained in New Guide
-
Remergify and Ready Set Fund Grow Launch Municipal Opportunity Zone Framework to Modernize Core Public Utilities and Bridge the Divide Between Luxury Growth and Community Stability
-
CreditRiskMonitor Trade Contributors Use New Self-Serve Feature
-
Caldwell Expands Leadership Advisory With Launch of Caldwell Leadership Intelligence
-
neoseek Builds on a Decade of Engineering Expertise to Accelerate Global Expansion in Portable Charging
-
Medical Care Technologies Inc. (OTCID:MDCE) Pauses Dilution Through 2027 After Q3 Profitability Rebound and Infinite Auctions Private Sales Exceed $300,000 in Q4
-
Route1 Announces Issuance of Shares for Compensation
-
Modular Medical Secures Coverage Agreements with All Three of the Nation's Largest PBMs for Pivot Insulin Delivery System
-
After 20 Years of Modernizing Other Companies' Software, Polcode Turns the Lens on Itself
-
Celtic Bank Selects Infinant to Scale Its Embedded Finance Programs
-
BlackBerry and Hazard Management Cayman Islands Renew Critical Alerting System for Emergencies and Public Safety
-
Philadelphia Sexual Assault Lawyer David P. Thiruselvam Explains Who Can Be Named in a Civil Sexual Assault Claim
-
Metano Emerges From Stealth to Unify AI Agent Security Across the Enterprise
-
ATWEC Technologies, Inc. (OTCID: ATWT) Engages Michael Gillespie & Associates, PLLC to Audit Fiscal 2026 and 2025 Consolidated Financial Statements and Changes Fiscal Year End to October 31
-
Vogenx Set to Join the Russell 2000(R), Russell 3000(R), and Russell Microcap(R) Indexes
-
Stemtech Corporation Partners with Fitness Icon Tony Little to Launch Stemtech Biosciences Digital Campaign
-
Go Green Global Technologies Corp. Appoints Dennis Beckert as Interim Chief Executive Officer
-
InstaLILY Launches Lily for Sales on Microsoft Dynamics 365, Where Sellers and AI Agents Work Together in Shared Rooms
-
Wave AI, the AI Note Taker for In-Person Meetings, Passes 5 Million Recorded Hours
-
Increasing Electrification Raises Grid Risk and Cost Pressure for Industrial Sites, ABI Research Finds
-
Jerash Holdings Partners with International Finance Corporation (IFC) to Pursue EDGE Gender Certification
MIRA Pharmaceuticals Reports Positive PTSD Data Demonstrating Ketamir-2 Restores Normalized Behavior in Stressed Animals
MIRA advances Ketamir-2 in the clinic for neuropathic pain while broadening development into neuropsychiatric disorders such as PTSD
MIRA advances Ketamir-2 in the clinic for neuropathic pain while broadening development into neuropsychiatric disorders such as PTSD
MIAMI, FLORIDA / ACCESS Newswire / September 16, 2025 / MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) ("MIRA" or the "Company"), a clinical-stage pharmaceutical company developing novel oral therapeutics for neurologic, neuropsychiatric, and metabolic disorders, today announced positive results demonstrating that its oral drug candidate Ketamir-2 restored normalized behavior in stressed animals within a validated model of post-traumatic stress disorder (PTSD). Ketamir-2 is currently being evaluated in an ongoing Phase 1 clinical trial for neuropathic pain, where it has shown a favorable safety profile to date.
"Restoring behavior to normal in a stressed PTSD model represents an important step forward," said Erez Aminov, CEO of MIRA Pharmaceuticals. "These findings support our decision to broaden the scientific evaluation of Ketamir-2 beyond neuropathic pain into neuropsychiatric disorders such as PTSD. Looking ahead, we plan to explore opportunities for potential collaborations, including with military and government institutions, given the significant unmet need for effective PTSD treatments."
This proof-of-concept validation study was conducted in a small group of rats using the Single Prolonged Stress (SPS) model, a widely accepted paradigm for inducing inescapable stress that mimics PTSD symptoms in animals. Animals were exposed twice to a predator stressor (bobcat urine), which is known to induce "depression-like" symptoms and changes in active/passive coping. Increased immobility after stress exposure reflects enhanced affective impairment or reduced stress resilience. Following the development of these symptoms, animals were dosed orally with Ketamir-2 once daily for five consecutive days.
Behavioral assessments included anxiety- and coping/resilience-related behavior in the forced swim test (FST), which measures immobility versus active coping strategies.
Outcome: stressed animals displayed hallmark PTSD-like behaviors, including increased despair, immobility, and avoidance of coping. Treatment with Ketamir-2 reversed these types of behaviors, restoring them toward the level observed in non-stressed animals. This initial validation supports the study design, and a larger follow-on PTSD study is ongoing.
"These preliminary results reinforce the therapeutic potential of Ketamir-2 in PTSD," said Dr. Itzchak Angel, Chief Scientific Advisor of MIRA. "We observed consistent reversal of stress-induced behavioral changes, supporting continued investigation of Ketamir-2 across neuropsychiatric disorders."
PTSD: A Major Unmet Need
PTSD affects an estimated 13 million adults in the United States each year, with approximately 6% of U.S. adults experiencing PTSD at some point in their lives.
The economic and social burden of PTSD is estimated at $232 billion annually in the U.S., driven by lost productivity, medical care, and disability.
The treatment landscape is limited:
Only two FDA-approved medications exist for PTSD (sertraline and paroxetine, both SSRIs), which provide limited relief and are often poorly tolerated (FDA PTSD treatments).
Psychotherapies such as CBT and EMDR can be effective, but access, adherence, and dropout rates remain significant challenges.
The U.S. Department of Defense and Veterans Affairs continue to invest heavily in novel PTSD research, underscoring the urgent need for safer and more effective solutions for service members and veterans.
About Ketamir-2
Ketamir-2 is a proprietary, orally bioavailable new molecular entity that selectively targets the NMDA receptor (PCP site) with low affinity and demonstrates no significant off-target activity across a broad receptor panel. Ketamir-2 was designed to capture the therapeutic efficacy of ketamine while minimizing the unwanted dissociative and other central nervous system side effects that limit ketamine's clinical use. The U.S. Drug Enforcement Administration's scientific review of Ketamir-2 concluded that it would not be considered a controlled substance or listed chemical under the Controlled Substances Act and its governing regulations. Previous animal studies have also shown Ketamir-2's superior efficacy versus ketamine, pregabalin, and gabapentin in neuropathic pain models.
Cautionary Note Regarding Forward-Looking Statements
This press release and the statements of MIRA's management related thereto contain "forward-looking statements," which are statements other than historical facts made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements may be identified by words such as "aims," "anticipates," "believes," "could," "estimates," "expects," "forecasts," "goal," "intends," "may," "plans," "possible," "potential," "seeks," "will," and variations of these words or similar expressions that are intended to identify forward-looking statements. Any statements in this press release that are not historical facts may be deemed forward-looking. Any forward-looking statements in this press release are based on MIRA's current expectations, estimates, and projections only as of the date of this release and are subject to a number of risks and uncertainties (many of which are beyond MIRA's control) that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements, including related to MIRA's potential merger with SKNY Pharmaceuticals, Inc. These and other risks concerning MIRA's programs and operations are described in additional detail in the Annual Report on Form 10-K for the year ended December 31, 2024, and the Form 14A filed by MIRA on June 18, 2025, and other SEC filings, which are on file with the SEC at www.sec.gov and on MIRA's website at https://www.mirapharmaceuticals.com/investors/sec-filings. MIRA explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law.
Contact:
Helga Moya
[email protected]
(786) 432-9792
SOURCE: MIRA Pharmaceuticals
View the original press release on ACCESS Newswire
P.Hernandez--AT